Insider txns (12m)
14
Stock / equity
FULC Fulcrum Therapeutics, Inc.
- Company
- Fulcrum Therapeutics, Inc.
- Security
- Equity
- Size, estimated from filings
- Micro cap (under $300M)
- Insiders on record
- 10
- Latest trade on record
- July 17, 2026
FULC (Fulcrum Therapeutics, Inc.) has 14 disclosed insider transactions from 9 insiders in the last 12 months (6 open-market buys, 0 sales, about $1.5M at reported prices) and 0 congressional trades from 0 members of Congress. The most recent disclosure was filed July 20, 2026.
Open-market buys / sales
6 / 0
Congress trades (12m)
0
Distinct filers (12m)
9
Share price
Price and chart by TradingView for Fulcrum Therapeutics, Inc.. US share prices here are delayed, not real-time. The trade records on this page come from government filings, not from this chart.
FULC in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
BoughtSold
1 person accounts for the disclosed buying and selling in FULC over the last 12 months; the most active is TANG KEVIN with $1.5M.
Prices insiders traded at
What price did insiders buy and sell at? Each marker is one open-market trade at the share price reported on its Form 4.
▲ Bought▼ SoldAverage reported price that day
Insiders reported 6 open-market trades in FULC since Jul 13, 2026, at prices from $3.52 to $3.58; the most recent was a purchase at $3.52 on Jul 17, 2026. These are the prices on the filings, not adjusted for stock splits, and not a market price series.
Insider holdings over time
Is an insider building or unwinding a position? Shares held directly after each filing.
TANG KEVIN
TANG KEVIN reported 7,080,945 shares held after the latest filing, against 6,913,329 at the first on record.
Lobbying spend by quarter
How much has Fulcrum Therapeutics, Inc. reported spending on federal lobbying?
Fulcrum Therapeutics, Inc. reported $190K in lobbying over the last eight quarters, from filings matched by exact company name.
Insiders trading FULC
Everyone who filed a Form 4 for this ticker, by number of rows on record. "Bought" and "sold" count open-market purchases (code P) and sales only; awards, option exercises and shares withheld for tax are in the row count but not in those two columns.
| Insider | Role | Rows | Bought | Sold | Value bought | Value sold | Latest |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Insider | 6 | 6 | 0 | $1.5M | — | July 17, 2026 |
| Sanofi | Insider | 3 | 1 | 0 | $1.5M | — | July 22, 2019 |
| Banks Sonja | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| Dorton Katina | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| Ezekowitz Alan | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| GERAGHTY JAMES A | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| Gould Robert J | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| Haviland Kate | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| Hill Colin | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
| King Rachel K. | Director | 1 | 0 | 0 | — | — | June 30, 2026 |
What kind of transactions these are 3 Form 4 codes
| Code | Meaning | Rows | Shares | Value at reported prices |
|---|---|---|---|---|
| A | Grant or award | 8 | 256,000 | — |
| P | Open-market purchase | 7 | 511,312 | $3.0M |
| C | Conversion of a derivative | 2 | 3,714,285 | — |
What each code means: Form 4 transaction codes.
Insider transactions
| Filer | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| TANG KEVIN | Buy P | July 17, 2026 | July 20, 2026 | 3d | 50,945 | $4 | $179K | indirect | Form 4 ↗ | |
| TANG KEVIN | Buy P | July 16, 2026 | July 20, 2026 | 4d | 116,671 | $4 | $415K | indirect | Form 4 ↗ | |
| TANG KEVIN | Buy P | July 15, 2026 | July 15, 2026 | 0d | 107,377 | $4 | $382K | indirect | Form 4 ↗ | |
| TANG KEVIN | Buy P | July 14, 2026 | July 15, 2026 | 1d | 75,952 | $4 | $272K | indirect | Form 4 ↗ | |
| TANG KEVIN | Buy P | July 14, 2026 | July 15, 2026 | 1d | 53,651 | $4 | $191K | indirect | Form 4 ↗ | |
| TANG KEVIN | Buy P | July 13, 2026 | July 15, 2026 | 2d | 12,966 | $4 | $46K | indirect | Form 4 ↗ | |
| Ezekowitz Alan | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Hill Colin | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| GERAGHTY JAMES A | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| King Rachel K. | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Haviland Kate | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Gould Robert J | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Dorton Katina | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Banks Sonja | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Sanofi | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 3,250,000 | — | — | indirectderivative | Form 4 ↗ | |
| Sanofi | Buy P | July 22, 2019 | July 23, 2019 | 1d | 93,750 | $16 | $1.5M | indirect | Form 4 ↗ | |
| Sanofi | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 464,285 | — | — | indirect | Form 4 ↗ |
Congressional trades
No member of Congress has disclosed a trade in this ticker in the filings we have parsed.
Related stocks
Tickers traded by the same people who traded FULC, by number of filers in common. It shows overlap in public filings and nothing else.
- REGN Regeneron Pharmaceuticals, Inc. - Common Stock 1 filer in common
- OGN Organon & Co. Common Stock 1 filer in common
- ATTO Attovia Therapeutics, Inc. 1 filer in common
- LTGO Latigo Biotherapeutics, Inc. 1 filer in common
- ICVX Icosavax, Inc. 1 filer in common
- INZY Inozyme Pharma, Inc. 1 filer in common
- TBIO Translate Bio, Inc. 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 11 | 17 | July 23, 2019 | July 20, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insider rows are Form 4 filings for this issuer from SEC EDGAR; congressional rows are periodic transaction reports parsed from the House Clerk and the Senate eFD. Values use the reported price for Form 4 and the disclosed range for Congress. See methodology and corrections.
Not investment advice. Disclosures are shown as filed and may lag the trade or be amended. No recommendation is made or implied.